Evidence map›Paper›PMID 33015156›Full record

ArticleBioMed research international2020

miR-9, miR-21, miR-27b, and miR-34a Expression in HPV16/58/52-Infected Cervical Cancer.

Mi Liu, Wei Wang, Haixing Chen, Yi Lu, Daisha Yuan, Yongjiu Deng, Danlu Ran

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Cervical Cancer, Papillomavirus, and miRNA Dysfunction.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mi LiuDepartment of Clinical Laboratory, The Tumor Hospital of Guizhou Province, Guiyang, 550004 Guizhou, China.ORCID https://orcid.org/0000-0001-6480-9448
Wei WangDepartment of Clinical Laboratory, The Tumor Hospital of Guizhou Province, Guiyang, 550004 Guizhou, China.
Haixing ChenDepartment of Clinical Laboratory, The Tumor Hospital of Guizhou Province, Guiyang, 550004 Guizhou, China.
Yi LuDepartment of Clinical Laboratory, The Tumor Hospital of Guizhou Province, Guiyang, 550004 Guizhou, China.
Daisha YuanDepartment of Clinical Laboratory, The Tumor Hospital of Guizhou Province, Guiyang, 550004 Guizhou, China.
Yongjiu DengClinical Laboratory Medicine, Guizhou Medical University, Guiyang, 550004 Guizhou, China.
Danlu RanClinical Laboratory Medicine, Guizhou Medical University, Guiyang, 550004 Guizhou, China.
Guizhou Cancer Hospital · CNGuiyang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to observe the expression of miR-9, miR-21, miR-27b, and miR-34a related with E6/E7 in HPV16-, HPV52-, and HPV58-infected cervical cancer patients and explore their possible role in cervical cancer with HPV infection. The expression levels of 4 miRNAs were detected in cervical exfoliated cells using qRT-PCR. In the current study, miR-34a expression was significantly upregulated in HPV-positive cervical cancer compared with the HPV-negative healthy population and HPV-positive CIN, but just the expression of miR-34a in HPV16 cervical cancer was statistically significant, and the expression of HPV52 and HPV58 was not statistically significant. The expression of miR-21 increased in HPV-positive cervical cancer compared with HPV-positive CIN, but only HPV16-infected cervical cancer had statistical significance compared with HPV16-infected CIN. By observing the change trend of each subtype group, we can show that the expression of miR-9 in HPV16 CIN was opposite to the other subtypes, and it was upregulated, compared with HPV58 CIN, and significantly increased. The level change of miR-27b in HPV58 cervical cancer and HPV58 CIN was opposite to the other subtypes; unlike the expression of miR-27b which was upregulated in HPV16 and HPV52 infected, it was downregulated compared with Normal. We also found that the expression of miR-34a and miR-9 was contrary to other studies. These findings indicate that the upregulated miR-21 expression may be a biomarker to distinguish between CC and CIN. miR-34a in HPV infection, especially in HPV16 infection, might be related to the occurrence and development of cervical cancer. The infection of different subtypes may play different roles in disease by activating different mechanisms; miRNAs play a very complex role in tumorigenesis and development, and there may be multiple targets in which multiple mechanisms play a role.

Indexed as

AdultBiomarkers, TumorCervix UteriDNA, ViralFemaleHumansMicroRNAsPapillomaviridaePapillomavirus InfectionsUp-RegulationUterine Cervical NeoplasmsBiomarkers, TumorDNA, ViralMicroRNAsMIRN21 microRNA, humanMIRN27b microRNA, humanMIRN34 microRNA, humanMIRN92 microRNA, human

Identifiers

PMID33015156
PMCPMC7519443
OpenAlexW3087271688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.